

Background

Applicant Information

(Carefully read the instructions before completing this form)

1. Applicant Information

Your User Profile information appears below however this section should indicate where the research described within this proposal will take place (change as necessary). NOTE: Your User Profile is always considered your current mailing address. The address listed here will be used to advise you of the outcome of this competition only.

- | | | | | | |
|-------------------|----------|--------------------------|--------------------------|--------------------------|----------------------------|
| a. Applicant Name | Title | <input type="radio"/> Dr | <input type="radio"/> Mr | <input type="radio"/> Ms | <input type="radio"/> Prof |
| b. Institution | | | | | |
| c. Department | | | | | |
| d. Address 1 | | | | | |
| e. Address 2 | | | | | |
| f. Address 3 | | | | | |
| g. Address 4 | | | | | |
| h. Country | | | | | |
| i. City | Province | | | Postal Code | |
| j. Phone | Ext | | | Fax | |
| k. e-Mail Address | | | | | |
| l. Designation | | | | | |

2. Project Information

The title entered when the application was created is indicated. Please avoid typing in ALL CAPS. In addition, ensure the end date of your project is updated.

- | | | | |
|--|---|--------------------------------------|--|
| a. Project Title | | | |
| b. Is Financial Institution the same as the Research Institution? (Please select Yes or No) | <input type="radio"/> Yes | <input type="radio"/> No | |
| c. If No, provide Financial Institution name | | | |
| d. Project Start Date | End Date | | |
| e. Amount of Funds Requested | Project Cost | | |
| f. Type of application. Note: maximum 1 application allowed per PI/Co-PI per competition (Please select one from list) | | | |
| | <input type="radio"/> Initial Application | <input type="radio"/> Re-application | |
| g. Include my application under the CCS breast cancer call. Please refer to the Innovation Grant program description page on cancer.ca/research for more information about the call. | <input type="radio"/> Yes | <input type="radio"/> No | |
| h. Include my application under the CCS skin cancer call. Please refer to the Innovation Grant program description page on cancer.ca/research for more information about the call. | <input type="radio"/> Yes | <input type="radio"/> No | |
| i. Include my application under the CCS malignant mixed Müllerian tumours (MMMT) cancer call. Please refer to the Innovation Grant program description page on cancer.ca/research for more information about the call. | <input type="radio"/> Yes | <input type="radio"/> No | |
| j. Do applicants confirm that there is no overlap with any other pending application (including those at the abstract registration or Letter of Intent submission stage) to any other agency as of October 15, 2019? | <input type="radio"/> Yes | <input type="radio"/> No | |
| k. Indicate the number of years of support requested (term can extend over 3 years) | | | |

-
1. Is this application being submitted in French? (Note that all review panels are conducted in Yes No English.)

SAMPLE

3. Participants

Enter the Financial Officer and any Co-Principal Investigator, Co-Applicant, Additional Author and Collaborator information applicable to your application. Use the lookup feature and enter the participant's email address in the field provided as the search criteria. The form will be auto-populated with their contact information as it appears in their user profile. If they do not have a profile, enter the participant's details as required.
 Please attach a CV for all participants (excluding the Financial Officer and Collaborators) and use the format: [lastname_firstname-CV].
 For collaborators, please attach the corresponding letter of support and use the format: [lastname_firstname-collaboration]..

a. Additional Author

- Name
- Title
- Institution
- Department
- Address 1
- Address 2
- Address 3
- Address 4
- Country
- City
- Province
- Postal Code
- Telephone
- Fax
- E-Mail Address

b. Co-Applicant


- Name
- Title
- Institution
- Department
- Address 1
- Address 2
- Address 3
- Address 4
- Country
- City
- Province
- Postal Code
- Telephone
- Fax
- E-Mail Address

c. Collaborator

- Name
- Title
- Institution
- Department
- Address 1
- Address 2
- Address 3
- Address 4
- Country
- City
- Province
- Postal Code
- Telephone
- Fax
- E-Mail Address

d. Co-Principal Investigator

- Name
- Title



Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

e. Financial Officer

Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address



Applicant info

4. Principal Investigator CV

Attach your abbreviated CV (not exceeding 3 single-spaced pages) in PDF format. It should include the following information: academic degrees; details of employment since graduation; list of publications during the last 5 working years; and grant support in the past 5 years. Please see the Application Guide for more details. NOTE: For the file name, please use the following format: [lastname_firstname-CV]. CCS is not a member organization of the Common CV Network, therefore the Common CV should not be used due to Common CV use restrictions.

5. Application and Career stage

This section is mandatory and plays no part in the review or funding of an application. The data is used for statistical and communication purposes only.

Please indicate below if this is:

Your first application for a research grant to the Canadian Cancer Society Yes No

Your first application for a research grant specifically in the area of cancer research Yes No

Your first application for a research grant as an independent investigator Yes No

Please indicate your current career stage (please select one of the three options):

- New/early career investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) no more than 5 years ago (60 months).
- Mid-career investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) 5-15 years ago.
- Senior investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) more than 15 years ago.

6. Biographical information (optional)

This section is optional and plays no part in the review or funding of an application. The data is used for statistical and communications purposes only.

Gender

Male Female

Date of birth - month

Day

Year

Birth city

Birth province

Birth country

City raised

Country raised

Language(s) spoken

Citizenship

Certificates

7. Certificates required

7.a. Biohazard/Biosafety

Indicate if certificates will be required. Certificates will be requested at the time of funding.

- a. Does your project require a biohazard certificate? Yes No
- b. Are biohazard certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? Yes No
- c. If yes, give details.

List of other institutions

7.b. Animal care

Indicate if certificates will be required. Certificates will be requested at the time of funding.

- a. Does your project require animal care certificates? Yes No
- b. Are animal care certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? Yes No
- c. If yes, give details.

List of other institutions

7.c. Ethics

Indicate if certificates will be required. Certificates will be requested at the time of funding.

- a. Does your project require ethics certificates? Yes No
- b. Are ethics certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? Yes No

c. If yes, give details.

List of other institutions

7.d. Human samples

Indicate if human samples will be used. Appropriate evidence demonstrating that the PI has registered/enrolled for bio-specimen collection with a quality assurance program will be requested at the time of funding. This applies equally to all prospective (new) bio-specimens used in the CCS-funded research that will be collected and/or all retrospective (old) bio-specimens used in the CCS-funded research that have previously been collected and will come from a biobank(s).

- a. Does your project involve the use of human samples? Yes No
- b. Does your project involve the use of human samples from more than one biobank? Yes No
- c. Please list details.

List of all biobanks to be used

8. Human embryonic stem cells involvement

Any applicant who proposes the creation or use of human embryonic stem cells, or proposes any research that would fall under the federal legislation or the CIHR Guidelines must clearly indicate this fact in the section provided, and must disclose all relevant details in the proposal.

Does the proposal involve the use or creation of human embryonic stem cells? (If yes, contact the CCS) Yes No

If yes, is the research reviewed under the auspices of the local ethics review board? (Do not answer this if the answer above is No)

Public summary

9. Need for project

What need – in research or health care – will be addressed by this project (i.e. what is the rationale)? (maximum 500 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

10. Goal of project

What is the goal of this project – what are you hoping to achieve? (maximum 500 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

11. Project description

How will you achieve this (reminder: please use nontechnical language)? (maximum 500 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

12. Future impact

How do you think this project could/will ultimately have an impact on the cancer community (including researchers, patients, families, policy, and the public at large, as relevant)? (maximum 650 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

Abstract

13. Scientific abstract

Provide a detailed summary of your research project (maximum of 4200 characters, including spaces), stating the problem to be investigated, the objectives of the investigation, the methodology to be used, as well as the significance of the research to cancer. Note that the character count may be different when copying text from Word due to formatting.

14. Non-confidential scientific abstract

For applications approved for funding, a non-confidential scientific abstract will be posted along with the funding results on the CCS research webpage.

Please include a duplicate of your scientific abstract – with proprietary information removed. This abstract may also be shared with potential donors and CCS stakeholders when relevant.

Your abstract should not exceed 4200 characters (including spaces), or roughly one full page, single spaced. Note that the character count may be different when copying text from Word due to formatting.

15. Keywords/Technical terms

Provide up to a maximum of ten specific keywords or descriptive technical terms/methodologies that best describe the scientific and technical aspects of your project. NOTE: Enter one keyword or technical term per line.

Keyword/Technical terms

16. Innovation statement

Describe how the project is transformational and innovative (maximum of 2,100 characters, including spaces). Ensure that the statement focuses on innovation and not significance. Note that the next logical step or incremental advancement on published data is not considered innovative. Character count may be different when copying text from Word due to formatting.

17. Vision statement

Describe how the proposed work will move the field forward and accelerate progress in cancer research (maximum of 1000 characters, including spaces). This statement should also clearly address the expected "next steps" following completion of the project. Note that the character count may be different when copying text from Word due to formatting.

SAMPLE

Proposal

18. Response to previous critique (re-applications only)

18.a. Response to previous critique (re-applications only)

If you are submitting your proposal as a re-application, provide a response (maximum 2100 characters, including spaces) indicating what improvements have been made as a result of the critiques from the last competition review panel. Note that the character count may be different when copying text from Word due to formatting.

18.b. Scientific Officer and reviewer reports (re-applications only)

If you are submitting your proposal as a re-application, attach the original, complete version of the scientific officer's report and unabridged reviews from the panel review generated from EGrAMS in PDF format. Do not re-format or alter the original PDF reviews in any way. NOTE: For the file name, please use the following format: [lastname_firstname-previous_reviews].

19. Table of Contents

OPTIONAL: Include a brief table of contents to help guide the reviewer through the proposal.

20. Proposal

Provide a scientific proposal (maximum of 17000 characters, including spaces) clearly stating the:

1. aims of the project - Investigators must provide a compelling rationale for the hypothesis. Overly-ambitious aims are discouraged.
2. experimental design, methods and analysis. Preliminary data may be included, but is not a requirement.
3. details of which member(s) of the research team will be responsible for which aspect of the project, including a rationale for their inclusion in the project, and a description of the research environment where the work will take place.

Note that the character count may be different when copying text from Word due to formatting. To insert special characters, you must use Alt codes or the special character tool in EGrAMS and not Symbol font.

21. Research team contributions

List each research team member (both those named on the grant as a Participant and any others not named), and indicate the % of the project work to be completed by each individual. The total % should add to 100, do not add a '%' sign in the '% of work' field.

Participant	Percent of the project work

22. Tables, graphs, charts and associated legends

OPTIONAL: Attach and appropriately label figures, graphs, charts and legends in PDF format (maximum of 2 pages total and 5MB in size). Eligible figures, tables and charts can include graphs, diagrams displaying data or non-data schematics/flow diagrams as well as project timelines. Tables should not include descriptions of how work will be carried out (e.g. description of team responsibilities, research plan, etc.), as these descriptions should be included within the proposal.

NOTE: For the file name, please use the following format: [lastname_firstname-figures].

23. List of references

Provide a list of references cited within the proposal. A standard reference style is recommended (e.g. first author, article title, journal title, date of publication, volume, issue, location (pagination)).

24. Appendices

OPTIONAL: Note that all essential information must be included in the proposal and that reviewers are not required to read the material in the appendices. Attachments must be in PDF format only and can not exceed 10MB per attachment. NOTE: For the file name, please use the following format: [lastname_firstname-appendix1].

25. Disclosure of commercial or conflict of interest related to this application

If any of the named investigators have a financial interest in any commercial venture whose business activities are related to the subject matter of this grant application, the nature of that interest must be disclosed and a description of how conflict of interest, if any, will be managed should be provided. Please describe the nature of the relationship or material interest, the business activities of the company in question, and how those activities relate, if at all, to the grant application.

- a. Do applicants have any commercial or conflict of interest to declare? Yes No
- b. If Yes, please provide a description of the commercial or conflict of interest and how it will be managed.

SAMPLE

Budget

Description	2020	2021	2022	Total
DIRECT EXPENSES				
Program Expenses				
1	Supplies and Expenses			
2	Salaries and Wages			
Total Program Expenses	0.00	0.00	0.00	0.00
Equipment				
1	Permanent Equipment			
Total Equipment	0.00	0.00	0.00	0.00
TOTAL DIRECT EXPENSES	0.00	0.00	0.00	0.00
TOTAL EXPENDITURES	0.00	0.00	0.00	0.00

SAMPLE

Description	2020	2021	2022	Total
Program Expenses				
Supplies and Expenses	0.00	0.00	0.00	0.00
Salaries and Wages	0.00	0.00	0.00	0.00
Total for Program Expenses	0.00	0.00	0.00	0.00
Permanent Equipment	0.00	0.00	0.00	0.00
TOTALS	0.00	0.00	0.00	0.00

SAMPLE

Other funding

28. Summary of other funding applied for and received

List all grants currently being applied for, pending, about to be submitted and all grants received, for the entire period covered by this application, for the Principal Investigator and each Co-Principal Investigator. Your documentation should include a list followed by the abstracts/summaries, as submitted in the original application for funding, for all grants/applications listed and should be submitted in PDF format. For pending grant applications with similar titles, please include a statement explaining overlap, or lack thereof. Consult the Application Guide for complete instructions, including the correct format. If there are no pending grants to list, indicate by including N/A in the Pending grants section. Applications with missing other funding information or abstracts will be considered incomplete.

NOTE: For the file name, please use the following format: [lastname_firstname-other_funding]

29. Other funding confirmation

- The applicants confirm that the attached list contains all required information, including the percentage overlap for each grant and the abstracts as submitted in the original application for funding, as described in the Application Guide.

SAMPLE

Review panel

30. Panel recommendation

Applicants may recommend which grant panel might be the most appropriate to review the application. Please suggest first and second choices of those panels considered to have the expertise necessary for peer review of the application.

- a. 1st choice of panel suggested by applicant(s):
- b. 2nd choice of panel suggested by applicant(s):
- c. Assigned Panel

31. Reviewer recommendation

Applicants must suggest the names of at least 3 (5 if submitting application in French) impartial reviewers who have the necessary expertise to critically evaluate the application and with whom you do NOT collaborate.

Name	Department	Institution	Phone no.	E-mail address	Areas of expertise

32. Reviewer exclusions

Applicants may suggest individuals they prefer NOT be contacted as potential reviewers (panel members and/or external reviewers). The reason for exclusion (e.g. collaborator, colleague, competitor) should be given. NOTE: any exclusions you list will be viewable to all panel members assigned to review your application.

Name	Reason for exclusion

Tracking

33. Research tracking information

33.a. Research focus

Responses are to be limited to the scope of the proposed research for the duration of the proposed term. This information is used solely for statistical/reporting purposes and will not be used as part of the scientific review of the application. Select the research focus of the proposal.

I. SECTION I - Research focus (select ONE only)

- Biomedical Research
 Clinical Research
 Health Services/Systems Research
 Social, Cultural, Environmental and Population Health

33.b. Research subject

Select the research subject(s).

II. SECTION II - Research subject (select ONE or MORE)

Patients/Study Population

- Adult
 Pediatric
 Adolescents & Young Adults

Patient Tissue

- Adult
 Pediatric
 Adolescents & Young Adults

Model System

- Mouse
 Drosophila
 C. elegans

- Zebrafish

- Yeast

- Other

Cell System

- hESC

- Tumour Initiating Cell

- Non-embryo-derived stem cells (eg. iPS cells)

33.c. Cancer site relevance

Select a maximum of 3 cancer sites where the research will be most relevant. Indicate the degree of relevance (percentage). The total should equal 100%. Only use the Details description field to describe the site if you have selected Other as a site. Note: Do not enter a % sign with your percentage, only enter the number.

III. SECTION III - Cancer site relevance

Cancer site relevance	Percentage	Details

33.d. Common Scientific Outline (CSO)

Select a maximum of 3 codes which best describe the research. Full details of the Common Scientific Outline can be found at the International Cancer Research Portfolio website (<https://www.icrpartnership.org/cso>).

IV. Section IV - Common Scientific Outline (CSO)

Biology

- 1.1 Normal functioning
 1.2 Cancer initiation: alterations in chromosomes
 1.3 Cancer initiation: oncogenes and tumour suppressor genes
 1.4 Cancer progression and metastasis

- 1.5 Resources and infrastructure

Etiology

- 2.1 Exogenous factors in the origin and cause of cancer
- 2.2 Endogenous factors in the origin and cause of cancer
- 2.3 Interactions of genes and/or genetic polymorphisms with exogenous and/or endogenous factors
- 2.4 Resources and infrastructure related to etiology

Prevention

- 3.1 Interventions to prevent cancer: personal behaviors (non-dietary) that affect cancer risk
- 3.2 Dietary interventions to reduce cancer risk and nutritional science in cancer prevention
- 3.3 Chemoprevention and other medical interventions
- 3.4 Vaccines
- 3.5 Complementary and alternative prevention approaches
- 3.6 Resources and infrastructure related to prevention

Early Detection, Diagnosis and Prognosis

- 4.1 Technology development and/or marker discovery
- 4.2 Technology and/or marker evaluation with respect to fundamental parameters of method
- 4.3 Technology and/or marker testing in a clinical setting
- 4.4 Resources and infrastructure related to detection, diagnosis and prognosis

Treatment

- 5.1 Localized therapies – discovery and development
- 5.2 Localized therapies – clinical applications
- 5.3 Systemic therapies – discovery and development
- 5.4 Systemic therapies – clinical applications
- 5.5 Combinations of localized and systemic therapies
- 5.6 Complementary and alternative treatment approaches
- 5.7 Resources and infrastructure related to treatment and the prevention of recurrence

Cancer Control, Survivorship and Outcomes Research

- 6.1 Patient care and survivorship issues
- 6.2 Surveillance
- 6.3 Population-based behavioral factors
- 6.4 Health services, economic and health policy analyses
- 6.5 Education and communication research
- 6.6 End-of-life care
- 6.7 Research on ethics and confidentiality
- 6.8 Historical code - no longer used
- 6.9 Resources and infrastructure related to cancer control, survivorship and outcomes research

Release form

34. Release form

The CCS depends on donor dollars to fund its grants. Applicants must declare their willingness to allow CCS to provide minimal details of their grant to potential donors/partners. For successful investigators, the grantee must declare their understanding that CCS will post competition results (PI, HI, title, value of grant, lay summary) on our website and potentially include a lay summary of the progress and impact of the research in our reports to donors/the public, press releases, social media or other communications.

On condition that:

- the specified information will be shared by CCS only with potential donors/partners and for the sole purpose of obtaining additional funding for CCS's grant competitions.
 - potential donors/partners will be required to declare conflict of interest, and sign a confidentiality agreement before the specified information is released to them by CCS.
 - it will be held confidential by them and not released to other parties, and will be returned to CCS or destroyed if the decision is not to fund.
 - all information released may be retained by the potential donors/partners if it decides to fund the application, and may be used by the donor/partner in its funding announcements and other communications.
- I acknowledge the sharing of the information specified with potential donors/partners and if successful in the competition, CCS will announce the grant and may publish research impacts (described above).

Head of Department

35. Head of Department/Dean confirmation

This section can only be completed by the Head of the applicant's research department. If the project is to be carried out by the Head of the Department the application must instead be confirmed by the Dean. As the Head of Department/Dean your online acknowledgement indicates that you are aware of the contents of the application being submitted. Answer the question below, then click on Save to complete your confirmation.

I confirm that I am aware of the contents of the application being submitted.

Yes No

Name of the Head of Department or Dean

Title

Research Institution

Financial Institution

Date

SAMPLE

Executive authority - research host**36. Executive authority of the host research institution**

This section can only be completed by an executive authority of the host Institution within which the research will be conducted. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement and agree to abide by the terms. Yes No

Name of the Executive Authority - research host

Title

Research Institution

Financial Institution

Date

SAMPLE

Executive authority - financial host**37. Executive authority of the host finance institution**

This section can only be completed by an executive authority of the Institution within which the funds will be administered. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement, and agree to abide by the terms. Yes No

Name of the Executive Authority - financial host

Title

Research Institution

Financial Institution

Date

SAMPLE

Post submission publications

38. Post submission publications

Publication lists included in this section prior to submission will be removed. This section should only be used after you have submitted your application. Attach a PDF document of your acceptance e-mail/letter for newly accepted publications. You may update this attachment at any time after you've submitted your application, up until the panel meeting. NOTE: For the file name, use the following format [lastname_firstname_publications_yyyymmdd], where yyyymmdd is the current date.

SAMPLE